medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2015, Número 2

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (2)


¿Es realmente asintomático el portador de la hemoglobina S?

Agramonte LOM, Expósito DY, Miguel MM, Zamora GY

Idioma: Español
Referencias bibliográficas: 57
Paginas: 102-112
Archivo PDF: 137.96 Kb.


RESUMEN

La controversia sobre si el estado de portador de la hemoglobina S debe ser visto como una enfermedad benigna o como un fenotipo intermedio de la anemia de células falciformes se mantiene hasta nuestros días. Los reportes de complicaciones renales, tromboembólicas y de muerte súbita relacionadas con el ejercicio en estos individuos, demandan la necesidad de un consenso en relación con este concepto. Nuestro objetivo es dirigir la atención hacia este grupo de personas que presentan una afectación genética de la síntesis de hemoglobina, identificar y detectar tempranamente complicaciones derivadas de esta condición genética, con el fin de proporcionarles una mejor atención médica y contribuir a definir si realmente el portador de la hemoglobina S es asintomático.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: a HUGE Review. Am J Epidemiol. 2000 May 1;151(9):839-45.

  2. World Health Organization. Sickle cell anemia. Report by the secretariat. 59th World Health Assembly. April 2, 2006.

  3. Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol. 1996;13(5):501-12.

  4. González R, Ballester JM, Estrada M, Lima F, Martínez G, Wade M, et al. A study of the genetical structure of the Cuban population: red cell and serum biochemical markers. Am J Hum Genet. 1976 Nov;28(6):585-96.

  5. Steinberg MH, Embury SH. Alfa-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood. 1986 Nov;68(5):985-90.

  6. Okoli K, Irani F, Horvath W. Pathophysiologic considerations for the interactions between obstructive sleep apnea and sickle hemoglobinopathies. Med Hypotheses. 2009 May;72(5): 578-80.

  7. Beaudry JT, Krause MA, Diakite SA, Fay MP, Joshi G, Diakite M, et al. Ex-vivo cytoadherence phenotypes of Plasmodium falciparum strains from Malian children with hemoglobins A, S, and C. PLoS One. 2014 Mar 19;9(3):e92185.

  8. Bougouma EC, Tiono AB, Ouédraogo A, Soulama I, Diarra A, Yaro JB, et al. Haemoglobin variants and Plasmodium falciparum malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso. Malar J. 2012 May 4;11:154.

  9. Taylor SM, Fairhurst RM. Malaria parasites and red cell variants: when a house is not a home. Curr Opin Hematol. 2014 May;21(3):193-200.

  10. Vigilante JA, DiGeorge NW. Sickle cell trait and diving: review and recommendations. Undersea Hyperb Med. 2014 May-Jun;41(3):223-8.

  11. Diaw M, Samb A, Diop S, Sall ND, Ba A, Cissé F, et al. Effects of hydration and water deprivation on blood viscosity during a soccer game in sickle cell trait carriers.Br J Sports Med. 2014 Feb;48(4):326-31.

  12. Peces R, Peces C, Cuesta-López E, Vega-Cabrera C, Azorín S, Pérez-Dueñas V. Co-inheritance of autosomal dominant polycystic kidney disease and sickle cell trait in African Americans. Nefrologia. 2011;31(2):162-8.

  13. Alappan N, Marak CP, Chopra A, Joy PS, Dorokhova O, Guddati AK. Renal medullary cancer in a patient with sickle cell trait. Case Rep Oncol Med. 2013;2013:129813

  14. Sears DA. The morbidity of sickle cell trait: a review of the literature. Am J Med. 1978 Jun;64(6):1021-36.

  15. Thogmartin JR, Wilson CI, Palma NA, Ignacio SS, Shuman MJ, Flannagan LM. Sickle cell trait-associated deaths: a case series with a review of the literature. J Forensic Sci. 2011 Sep;56(5):1352-60.

  16. Amar KO, Bourdonné O, Bruneau S, Sellami F, Richard P. Assessment of leucoreduction of sickle cell trait blood: quality of the filtered product. Blood Transfus. 2014 Jan;12 Suppl 1:s193-8.

  17. Ould Amar AK. Red blood cells from donors with sickle cell trait: a safety issue for transfusion? Transfus Med. 2006 Aug;16(4):248-53.

  18. American Red Cross. Blood donation eligibility guidelines. (citado july 26, 2014) Available at: http://www.redcrossblood.org/donating-blood/eligibilityrequirements

  19. Ahmed SG. Anaerobic storage of red blood cells: the need for caution regarding donor red cells with sickle cell trait. Blood Transfus. 2011 Jul;9(3):347.

  20. Jacob EK, Emery RL, Orrock JM, van Buskirk CM, Gandhi MJ. Filter failures with sickling hemoglobin. Transfusión. 2009 Aug;49(8):1535-6.

  21. Shiradhonkar S, Jha R, Rao BS, Narayan G, Sinha S, Swarnalata G. Acute cortical necrosis following renal transplantation in a case of sickle cell trait. Indian J Nephrol. 2011 Oct;21(4):286-8.

  22. Huang RS, Tholpady A, Wahed A, Chang B, Bai Y. Therapeutic plasmapheresis and red blood cell exchange in a sickle cell trait patient with rhabdomyolysis. J Clin Apher. 2012;27(6):342-5.

  23. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009 Jun;122(6):507-12.

  24. Key NS, Derebail VK. Sickle-Cell Trait: Novel Clinical Significance. Hematology Am Soc Hematol Educ Program. 2010;2010:418-22.

  25. Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg HM. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential Implications. Am J Hematol. 2012 March;87(3):340-6.

  26. Gill BS, Aragon-Ching JB, Perlin E. Hematuria in sickle cell trait: the importance of ruling out occult cancer. Ann Hematol. 2012 Jan;91(1):137-8.

  27. Ajayi AA, Kolawole BA. Sickle cell trait and gender influence type 2 diabetic complications in African patients. Eur J Intern Med. 2004 Aug;15(5):312-5.

  28. Bleyer AJ, Reddy SV, Sujata L, Russell GB, Akinnifesi D, Bleyer AJ Jr, et al. Sickle cell trait and development of microvascular complications in diabetes mellitus. Clin J Am Soc Nephrol. 2010 Jun;5(6):1015-20.

  29. Oli JM, Watkins PJ, Wild B, Adegoke OJ. Albuminuria in Afro-Caribbeans with Type 2 diabetes mellitus: is the sickle cell trait a risk factor? Diabet Med. 2004 May;21(5):483-6.

  30. Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Kshirsagar AV. High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol. 2010 Mar;21(3):413-7.

  31. Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, et al. Sickle cell trait is not independently associated with susceptibility to end–stage renal disease in Africans americans. Kidney Int. 2011 Dec;80(12):1339-43.

  32. Shetty A, Matrana MR. Renal medullary carcinoma: a case report and brief review of the literature. Ochsner J. 2014 Summer;14(2):270-5.

  33. Gill BS, Aragon-Ching JB, Perlin E. Hematuria in sickle cell trait: the importance of ruling out occult cancer. Ann Hematol. 2012 Jan;91(1):137-8.

  34. Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A, Dzik C. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors. 2013 Aug 20;5(3):e44.

  35. Kuypers FA, Marsh AM. Research in athletes with sickle cell trait: just do it. J Appl Physiol (1985). 2012 May;112(9):1433.

  36. Hosick, MB. Protocol decided for sickle cell testing. The NCAA News. ; Apr 13, 2010. (Citado Julio 27, 2014). Disponible en: http://www.meacsports.com/fls/20800/Compliance/Bulletins/LoopApril152010.pdf? DB_OEM_ID=20800 .

  37. Thompson AA. Sickle cell trait testing and athletic participation: a solution in search of a problem? Hematology Am Soc Hematol Educ Program. 2013;2013:632- 7.

  38. National Athletic Trainers’ Association. Consensus Statement: Sickle cell trait and the athlete. (citado agosto 13, 2014). Available at: http://www.docdatabase.net/more-consensus-statement-sickle-cell-trait-and-theathlete- 73046.html

  39. Diaw M, Diop M, Mbengue A, Sar FB, Hounkpevi C, Ouédraogo V, et al. Evaluation of erythrocyte deformability in subjects with sickle cell trait during a soccer game: effect of hydration ad libitum. Bull Soc Pathol Exot. 2013 May;106(2):95-9.

  40. Tripette J, Loko G, Samb A, Gogh BD, Sewade E, Seck D, et al. Effects of hydration and dehydration on blood rheology in sickle cell trait carriers during exercise. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H908-14.

  41. Vincent L, Feasson L, Oyono-Enguelle S, Banimbek V, Denis C, Guarneri C, et al. Remodeling of skeletal muscle microvasculature in sickle cell trait and alphathalassemia. Am J Physiol Heart Circ Physiol. 2010 Feb;298(2):375-84.

  42. Martins Wde A, Lopes HF, Consolim-Colombo FM, Gualandro Sde F, Arteaga- Fernández E, Mady C. Cardiovascular autonomic dysfunction in sickle cell anemia. Auton Neurosci. 2012 Jan;166(1-2):54-9.

  43. Sanya EO, Soladoye A, Olanrewaju TO, Kolo PM, Durotoye I. Cardiovascular autonomic reflex function in sickle cell anaemia patients. Niger Postgrad Med J. 2010 Dec;17(4):266-9.

  44. Oguanobi NI, Onwubere BJ, Anisiuba BC, Ike SO, Ejim EC, Ibegbulam OG. Clinical findings associated with cardiovascular autonomic dysfunction in adult sickle cell anaemia patients. Acta Cardiol. 2012 Apr;67(2):169-75.

  45. Romero JC, Hernández A, Agramonte O, Hernández P. Disfunción Autonómica Cardiovascular en Anemia Drepanocitica: factor de riesgo de muerte súbita?. Clin Auton Res. 1997 Jun;7(3):121-5.

  46. American Society of Hematology. Statement on Screening for Sickle Cell Trait and Athletic Participation. ASH Policy Statement 2012 (Published on Jan 26, 2012 ) (Citado July 28, 2014) Available in: http://www.hematology.org/Advocacy/Statements/2650.aspx.

  47. Abeysekera WY, de Silva WD, Pinnaduwa SS, Banagala AS. Acute massive splenic infarction with splenic vein thrombosis following altitude exposure of a Sri Lankan male with undetected sickle cell trait. High Alt Med Biol. 2012 Dec;13(4):288-90

  48. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jun;12(6):457-6.

  49. Gong L, Maiteki-Sebuguzi C, Rosenthal PJ, Hubbard AE, Drakeley CJ, Dorsey G, et al. Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood. 2012 Apr 19;119(16):3808-14.

  50. Ferreira A, Marguti I, Bechmann I, Jeney V, Chora A, Palha NR, et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell. 2011 Apr;145(3):398- 409.

  51. Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies: Slicing the Gordian knot of Plasmodium falciparum Malaria Pathogenesis. PLoS Pathog. 2013 May;9(5):e1003327.

  52. Linares M, Albizua E, Mendez D, Rubio JM, Martinez-Serna A, Martinez MA, et al. Malaria Hidden in a Patient with Diffuse Large-B-Cell Lymphoma and Sickle-Cell Trait. J Clin Microbiol. 2011 Dec;49(12):4401-4.

  53. McAuley CF, Webb C, Makani J, Macharia A, Uyoga S, Opi DH, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood. 2010 Sep;116(10):1663-8.

  54. Kiwuwa MS, Ribacke U, Moll K, Byarugaba J, Lundblom K, Färnert A, et al . Genetic diversity of Plasmodium falciparum infections in mild and severe malaria of children from Kampala, Uganda. Parasitol Res. 2013 Apr;112(4):1691-700.

  55. Walker PS, Reid ME. The Gerbich blood group system: a review. Immunohematology. 2010;26(2):60-5.

  56. Eridani S. Sickle cell protection from malaria. Hematol Rep. 2011;3:e24.

  57. Rosenthal PJ. Lessons from Sickle Cell Disease in the Treatment and Control of Malaria. N Engl J Med. 2011; 364(26):2549-51




2020     |     www.medigraphic.com